scispace - formally typeset
A

Alberto Rábano

Researcher at Carlos III Health Institute

Publications -  107
Citations -  4928

Alberto Rábano is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Medicine & Dementia. The author has an hindex of 31, co-authored 86 publications receiving 3366 citations. Previous affiliations of Alberto Rábano include Spanish National Research Council.

Papers
More filters
Journal ArticleDOI

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy

Günter U. Höglinger, +140 more
- 01 Jul 2011 - 
TL;DR: Two independent variants in MAPT affecting risk for PSP are confirmed, one of which influences MAPT brain expression and the genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface and for a myelin structural component.
Journal ArticleDOI

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Céline Bellenguez, +401 more
- 01 Apr 2022 - 
TL;DR: This paper performed a two-stage genome-wide association study with 111,326 clinically diagnosed/proxy AD cases and 677,663 controls and found 75 risk loci, of which 42 were new at the time of analysis.
Journal ArticleDOI

Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes.

Marta Pajares, +9 more
- 18 Jul 2016 - 
TL;DR: It is shown that NFE2L2 modulates autophagy gene expression and suggests a new strategy to combat proteinopathies.
Journal ArticleDOI

α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease

Isabel Lastres-Becker, +7 more
- 15 Jul 2012 - 
TL;DR: It is demonstrated that α-SYN and Nrf2 deficiency cooperate on protein aggregation, neuroinflammation and neuronal death and provides a bifactorial animal model to study early-stage PD.
Journal ArticleDOI

Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.

Isabel Lastres-Becker, +8 more
- 08 Jul 2016 - 
TL;DR: These experiments provide a compelling rationale for targeting NRF2 with DMF as a therapeutic strategy to reinforce endogenous brain defense mechanisms against PD-associated synucleinopathy and are ready for clinical validation in PD.